Hostname: page-component-54dcc4c588-tfzs5 Total loading time: 0 Render date: 2025-10-03T04:26:44.791Z Has data issue: false hasContentIssue false

Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study: commentary, Nielssen et al

Published online by Cambridge University Press:  04 September 2025

Olav Nielssen*
Affiliation:
Macquarie University, Sydney, NSW, Australia St Vincents Hospital Sydney, Sydney, NSW, Australia
Maryssa Portelli
Affiliation:
Royal Prince Alfred Hospital, Camperdown, NSW, Australia University of Sydney, Sydney, NSW, Australia
*
Correspondence: Olav Nielssen. Email: Olav.nielssen@mq.edu.au

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Commentary
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

El Baou, C, John, A, Lewer, D, Mandy, W, McKechnie, DGJ, Petersen, I, et al. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. Br J Psychiatry 2025; 226: 1–8.CrossRefGoogle Scholar
National Institute of Health and Care Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management. NICE, 2019 (https://www.nice.org.uk/guidance/ng87).Google Scholar
Khan, MU, Hasan, SS. Socioeconomic status and prescribing of ADHD medications: a study of ICB-level data in England. BMJ Ment Health 2025; 28: e301384.10.1136/bmjment-2024-301384CrossRefGoogle ScholarPubMed
Elliott, J, Johnston, A, Husereau, D, Kelly, SE, Eagles, C, Charach, A, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. PLoS One 2020; 15: e0240584.10.1371/journal.pone.0240584CrossRefGoogle ScholarPubMed
Tadrous, M, Shakeri, A, Chu, C, Watt, J, Mamdani, MM, Juurlink, DN, et al. Assessment of stimulant use and cardiovascular event risks among older adults. JAMA Netw Open 2021; 4: e2130795.10.1001/jamanetworkopen.2021.30795CrossRefGoogle ScholarPubMed
Zhang, L, Li, L, Andell, P, Garcia-Argibay, M, Quinn, PD, D’Onofrio, BM, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry 2024; 81: 178.CrossRefGoogle ScholarPubMed
Liang, EF, Lim, SZ, Tam, WW, Ho, CS, Zhang, MW, McIntyre, RS. The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): systematic review, meta-analysis, and meta-regression. Int J Environ Res Publ Health 2018; 15: 1789.10.3390/ijerph15081789CrossRefGoogle Scholar
Curtin, K, Fleckenstein, AE, Keeshin, BR, Yurgelun-Todd, DA, Renshaw, PF, Smith, KR, et al. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology 2018; 43: 2548.10.1038/s41386-018-0207-5CrossRefGoogle ScholarPubMed
Vasiliadis, HM, Lunghi, C, Rahme, E, Rochette, L, Gignac, M, Massamba, V, et al. ADHD medications use and risk of mortality and unintentional injuries: a population-based cohort study. Transl Psychiatry 2024; 14: 128.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.